Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 16, 2018. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing does not contain operational updates, earnings reports, or strategic business commentary.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on the London Stock Exchange (XLON) on July 12, 2018.
| Transaction Type | Instrument | Price per Share | Total Volume (Shares) |
|---|---|---|---|
| Acquisition via Dividend Re-investment | Ordinary Shares (25p each) | £15.7091 | 7,983.978 (Aggregated) |
Note: The total volume represents the sum of shares acquired by eight individuals listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine share acquisitions resulting from the re-investment of dividends paid to shareholders on July 12, 2018.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved senior executives including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and other senior leadership.
- Execution Date: All transactions occurred on July 12, 2018, at a uniform price of £15.7091 per share.
- Scope: This filing contains no financial performance data; investors should refer to GSK's Form 20-F or quarterly reports for revenue and profit metrics.